MEDEZE Stock Overview
Offers stem cell, NK cell, and follicle hair banking services in Thailand.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 4/6 |
Past Performance | 6/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Medeze Group Public Company Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ฿10.00 |
52 Week High | ฿13.80 |
52 Week Low | ฿9.80 |
Beta | 0 |
11 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -10.71% |
Recent News & Updates
Recent updates
Shareholder Returns
MEDEZE | TH Healthcare | TH Market | |
---|---|---|---|
7D | -7.4% | -1.2% | -1.3% |
1Y | n/a | -3.3% | 4.7% |
Return vs Industry: Insufficient data to determine how MEDEZE performed against the TH Healthcare industry.
Return vs Market: Insufficient data to determine how MEDEZE performed against the TH Market.
Price Volatility
MEDEZE volatility | |
---|---|
MEDEZE Average Weekly Movement | n/a |
Healthcare Industry Average Movement | 4.3% |
Market Average Movement | 5.1% |
10% most volatile stocks in TH Market | 11.0% |
10% least volatile stocks in TH Market | 2.6% |
Stable Share Price: MEDEZE's share price has been volatile over the past 3 months compared to the TH market.
Volatility Over Time: Insufficient data to determine MEDEZE's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | n/a | Veerapol Khemarangsan | www.medezegroup.com |
Medeze Group Public Company Limited offers stem cell, NK cell, and follicle hair banking services in Thailand. It also provides NK cell activity test and cosmeceutical skin care services, as well as biotech research and development services. The company was founded in 2010 and is based in headquartered in Sam Phran, Thailand.
Medeze Group Public Company Limited Fundamentals Summary
MEDEZE fundamental statistics | |
---|---|
Market cap | ฿10.68b |
Earnings (TTM) | ฿270.40m |
Revenue (TTM) | ฿780.07m |
39.5x
P/E Ratio13.7x
P/S RatioIs MEDEZE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MEDEZE income statement (TTM) | |
---|---|
Revenue | ฿780.07m |
Cost of Revenue | ฿167.21m |
Gross Profit | ฿612.85m |
Other Expenses | ฿342.46m |
Earnings | ฿270.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.25 |
Gross Margin | 78.56% |
Net Profit Margin | 34.66% |
Debt/Equity Ratio | 0% |
How did MEDEZE perform over the long term?
See historical performance and comparison